- Global Pharma News & Resources

Distributed Bio Inc. Announces Collaboration with H3 Biomedicine

Distributed Bio, the global leader in computational optimization of fully human monoclonal antibody libraries, today announced a discovery collaboration with H3 Biomedicine, Inc. designed to help accelerate the discovery of novel cancer therapeutics. The collaboration will leverage Distributed Bio’s proprietary SuperHuman antibody library platform to discover therapeutic-ready, preoptimized antibodies against H3 Biomedicine targets. H3 Biomedicine is a clinical stage biopharmaceutical company specializing in the discovery and development of next-generation cancer medicines using its data science and precision chemistry product engine.

“H3 Biomedicine is an exciting oncology company, with a novel approach to uncovering targets that could lead to new treatments for unmet needs in various types of cancer,” said Jacob Glanville Ph.D., Co-founder & CSO, Distributed Bio. “What was clear to us from the outset was that H3 Biomedicine’s goals would require significant advances to the normal antibody selection process. At Distributed Bio we are uniquely positioned to provide the advanced selection, screening and engineering techniques needed to advance important discovery programs.”

Under the terms of the agreement, Distributed Bio will discover antibodies by screening its SuperHuman antibody library with antigens provide by H3 Biomedicine. Multiple lead antibodies will be identified using a proprietary assay cascade. The antibodies generated through this method will be available to H3 Biomedicine to advance to clinical development. Distributed Bio will receive research funding and the opportunity for future milestone payments.

“At H3 Biomedicine, we are focused on uncovering novel cancer biology and rapidly translating those learnings to advance novel, first-in-class precision oncology medicines. As our lead clinical development programs continue to progress, we are also pursuing a broad portfolio of research programs and targets,” said Andrea Gerken, Vice President, Business Development at H3 Biomedicine. “As part of those research efforts, our collaboration with Distributed Bio will enable us to explore H3’s differentiated approach to antibody drug conjugates targeting RNA splicing.”

About Distributed Bio

Distributed Bio is a computational immunoengineering biotechnology group, self-funded by licensing a stack of technologies to partners across the pharmaceutical industry. Our mission is to disrupt biologic engineering with big data, machine learning, and computational immunology-driven design.

From a team that includes inventors of antibody repertoire sequencing technologies, their AbGenesis antibody and TCR repertoire analysis and engineering platform enables partners to analyze antibody repertoires by high-throughput sequence, sanger sequence, and functional assay without requiring large datacenter investments or local bioinformatics specialists. By using AbGenesis to analyze thousands of antibody repertoires and antibody libraries, they developed the computationally optimized SuperHuman antibody discovery platform. SuperHuman overcomes many of the limitation of other monoclonal generation technologies with an unprecedented diversity and developable fitness that has resulted in a unique engineering opportunity: a library that generates over 5000 unique hits against every antigen tested, including hundreds of unique picomolar binders against such challenging targets as PD1 and GHR. Given the number of hits, this library can be panned under unprecedented aggressive conditions, recovering hundreds of subnanomolar binders in under a week, recovering saturating coverage of hits against every epitope, and isolating multi-species cross-reactive members against target homologs without additional engineering.

View source version on

Editor Details

Last Updated: 30-Oct-2018